Skip to main content
No.1 Press Release Service in Korea
Search
Search
Login
Create Account
Services
Contact Us
News
Services
About Us
Contact Us
Korean
News
All News
News by Region
Korea
Overseas
News by Industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Services
Why Korea Newswire?
How We Distribute
Services & Pricing
Basic
Standard
Premium
Global
Translation
Press Release Network in Korea
Korean Language
About Us
News
Services
Contact Us
Search
Cancel
Search
Submit Press Release
Latest News
News by Region
Korea
World
News by Industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Health News Releases
Today April 22
August 23, 2022 17:00
Miracor Medical Announces FDA IDE Approval For PiCSO® Pivotal Study
Miracor Medical SA (Miracor Medical) has announced the approval of an Investigational Device Exemption (IDE) from the FDA, enabling the company to initiate a pivotal study with its Pressure-controlled
August 23, 2022 16:50
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment
August 23, 2022 16:20
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
Takeda (TSE:4502/NYSE:TAK) today announced the company’s dengue vaccine, QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), was approved by the Indonesia National Agency for Drug and F
August 23, 2022 14:00
Medisca Unveils New Brand Identity and Corporate Positioning as Partners in Wellness
After three successful decades of redefining, shaping, and informing the pharmaceutical compounding industry standard, Medisca is proud to unveil a new global brand identity and corporate positioning
August 23, 2022 11:35
Solasia Announces Launch of Darvias® in Japan
Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (S
August 22, 2022 16:30
VFMCRP announces U.S. Court upholds validity of Velphoro® patent
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251 whi
August 19, 2022 14:50
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Produ
August 18, 2022 16:40
Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a rituxim
August 10, 2022 11:10
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) will hold a meeting on September 22
August 05, 2022 11:10
GenomOncology and Congenica Announce Collaborative Development of Novel Precision Oncology Solution
Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a nov
August 04, 2022 17:25
ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial
ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States. Immu
August 04, 2022 15:45
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in a
August 04, 2022 14:40
SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination f
August 03, 2022 11:55
Adalvo Acquires Its First Branded Product, Onsolis®
The global pharmaceutical company Adalvo today announced the acquisition of its first branded product, Onsolis® after concluding a deal with a reputable US based specialty pharmaceutical Company, that
August 03, 2022 11:05
Wilhelm von Haller is Chief Financial Officer of Lysando AG
Lysando AG - market leader in the field of antimicrobial proteins - is pleased to announce that Wilhelm von Haller has joined the team as Chief Financial Officer this March. Baron von Haller is an exp
August 02, 2022 17:05
Finalization of Vifor Pharma acquisition
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Limited (ASX: CSL; USOTC:CSLLY) is pleased to announce it has now received all necessary regulatory clearances for the acquisition
August 02, 2022 11:30
Graminex®, L.L.C. Completes Clinical Trial with Graminex® Flower Pollen Extract Focusing on Women’s Urinary Incontinence with Positive Results.
Graminex®, L.L.C. is pleased to announce it has completed a clinical study with Graminex® Flower Pollen Extract for women’s urinary incontinence and urinary health with positive results. This study wa
July 29, 2022 14:00
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance.
July 29, 2022 11:20
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
Organon (NYSE: OGN), a global women’s healthcare company, and Cirqle Biomedical today announced they have entered into a research collaboration and exclusive license agreement for a novel investigatio
July 28, 2022 11:10
PCI Pharma Services Announces Multi-Million Dollar Expansion to UK Manufacturing Facility to Meet Growing Demand for Global High Potent Manufacturing Services Supporting Oncology Treatments
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced a significant expansion of its world-class facility in Tredegar, Wales, UK, desi
July 26, 2022 15:00
EssilorLuxottica Modernizes Order Processing With Boomi’s Intelligent Integration Platform
Boomi™, the intelligent connectivity and automation leader, today announced that EssilorLuxottica, a global leader in the eyewear market, has implemented Boomi's integration platform as a service (iPa
July 25, 2022 16:23
Increased Adoption of Imaging Technology To Detect And Monitor Ailment Severity Is Accelerating The Mobile Imaging Services Industry In Asia Pacific: Scrutinized Report By Fact.MR
The mobile imaging services market is predicted to account for USD 2.7 billion in 2032, up from USD 1.9 billion in 2022, advancing at a CAGR of 3.9% during the forecast period (2022-2032). The incr
July 22, 2022 16:10
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda (TSE:4502/NYSE:TAK) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombina
July 22, 2022 13:45
Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma
Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for the treatment of peripheral nerve injuries (PNI),
July 22, 2022 09:55
Siemens Korea Digital Industries Holds 9th Smart NC Contest Award Ceremony
Digital Industries (DI) of Siemens Korea (Siemens Ltd. Seoul·SLS) held the 9th Smart Numerical Control (NC) Contest Award Ceremony on July 21 at the Korea Digital Enterprise Experience Center (KDEXc)
«
38
39
40
41
42
»
25 per page
25 per page
50 per page
75 per page
100 per page
Distribute Your News to
KOREA
The largest press release distribution network in Korea
34,000 journalists
7,000 media outlets
345 industry channel
80,000 subscribers
Get Started
Global PR service
Reach Your Target
Audience in 160 Countries
powered by
Get Started
News by region
Korea
Overseas
News by industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Notice